Abstract
Purpose
To compare the drug efficacy of four prostaglandin analogues (PGAs) by bilateral treatment in normal subjects.
Methods
Three consecutive studies comparing latanoprost to three other PGAs (travoprost, tafluprost and bimatoprost) were performed in 24 healthy subjects. Each study was separated by a washout period of over 6 weeks. In each study, two drugs were randomly assigned to one eye of each subject. Study subjects instilled the assigned medication at 9:00 p.m. every day for 2 weeks. The same masked investigator measured intraocular pressure (IOP) at 9:00 a.m., 1:00 p.m. and 5:00 p.m. at baseline and repeated measurements on days 7 and 14. The differences in IOP reduction were compared between the drugs.
Results
Mean diurnal IOP reduction with latanoprost on days 7 and 14 was similar to that with travoprost and tafluprost, but was significantly lower than that with bimatoprost. The association of the mean diurnal IOP reduction between latanoprost and bimatoprost on day 14 (r 2 = 0.25) was weak, in remarkable contrast to the strong association between latanoprost and travoprost (r 2 = 0.81) and between latanoprost and tafluprost (0.82).
Conclusions
The short-term bilateral treatment revealed a different IOP-lowering efficacy of bimatoprost compared to other PGAs in healthy subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117–22.
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243–9.
van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279–83.
Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma. 2006;15:238–43.
Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153–7.
Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609–14.
Kaback M, Geanon J, Katz G, Ripkin D. START Study Group. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin. 2004;20:1341–5.
Sit AJ, Liu JH, Weinreb RN. Asymmetry of right versus left intraocular pressures over 24 hours in glaucoma patients. Ophthalmology. 2006;113:425–30.
Takahashi M, Higashide T, Sakurai M, Sugiyama K. Discrepancy of the intraocular pressure response between fellow eyes in one-eye trials versus bilateral treatment: verification with normal subjects. J Glaucoma. 2008;17:169–74.
Realini T, Vickers WR. Symmetry of fellow-eye intraocular pressure responses to topical glaucoma medications. Ophthalmology. 2005;112:599–602.
Lim KS, Nau CB, O’Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115:790–5.
Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23:385–94.
Casson RJ, Liu L, Graham SL, Morgan WH, Grigg JR, Galanopoulos A, et al. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. J Glaucoma. 2009;18:582–8.
Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005;46:4159–63.
Cantor LB, Hoop J, Wudunn D, Yung CW, Catoira Y, Valluri S, et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol. 2007;91:629–32.
Liang Y, Woodward DF, Guzman VM, Li C, Scott DF, Wang JW, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079–93.
Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–52.
Wakabayashi Y, Higashide T, Sugiyama K. Improved prediction of fellow-eye response in one-eye trials using multiple intraocular pressure measurements. Jpn J Ophthalmol. 2011;55:480–5.
Pandav SS, Sharma A, Gupta A, Sharma SK, Gupta A, Patnaik B. Reliability of ProTon and Goldmann applanation tonometers in normal and postkeratoplasty eyes. Ophthalmology. 2002;109:979–84.
Frenkel RE, Noecker RJ, Craven ER. Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03 % or travoprost 0.004 %. Curr Med Res Opin. 2008;24:919–23.
Mochizuki H, Itakura H, Yokoyama T, Takamatsu M, Kiuchi Y. Twenty-four-hour ocular hypotensive effects of 0.0015 % tafluprost and 0.005% latanoprost in healthy subjects. Jpn J Ophthalmol. 2010;54:286–90.
Conflict of interest
No author of this manuscript has a proprietary or financial interest in this study.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kawaguchi, I., Higashide, T., Ohkubo, S. et al. Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects. Jpn J Ophthalmol 56, 346–353 (2012). https://doi.org/10.1007/s10384-012-0155-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-012-0155-2